Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)30.16
  • Today's Change0.091 / 0.30%
  • Shares traded35.97k
  • 1 Year change+93.09%
  • Beta0.8607
Data delayed at least 15 minutes, as of Nov 22 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, mezagitamab (TAK-079), acimtamig (AFM13), AB054, ficlatuzumab (AV-299), COM902, vosaroxin, aldoxorubicin, INCAGN02385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], CMP-001 (vidutolimod), NTM-1631, NTM-1634, NTM-1633, NTM-1632, NIR178, MK-4830, AFM24, INCAGN01949, AB101, and CFZ533 (iscalimab).

  • Revenue in USD (TTM)21.61m
  • Net income in USD-35.43m
  • Incorporated2011
  • Employees13.00
  • Location
    XOMA Royalty Corp2200 Powell Street, Suite 310EMERYVILLE 94608United StatesUSA
  • Phone+1 (510) 204-7239
  • Fax+1 (302) 655-5049
  • Websitehttps://www.xoma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
XOMA:NMQ since
announced
Transaction
value
Kinnate Biopharma IncDeal completed16 Feb 202416 Feb 2024Deal completed35.98%99.33m
Data delayed at least 15 minutes, as of Nov 22 2024 20:59 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
AC Immune SA46.22m-44.97m325.51m133.00--2.22--7.04-0.4608-0.46080.47831.480.2116--3.19347,510.10-20.59-18.25-29.04-19.52-----97.29-148.29---14.570.0231--276.1415.5223.35---15.49--
Jasper Therapeutics Inc0.00-63.53m327.63m45.00--3.92-----4.75-4.750.005.580.00----0.00-60.56---68.51--------------0.00-------71.06------
Q32 Bio Inc0.00-49.66m329.37m42.00--17.94-----7.44-7.440.001.510.00----0.00-27.86-34.98-33.25-37.92-------971.76----0.4079---63.97-26.32-2,156.96---60.90--
AVITA Medical Inc60.04m-57.32m337.42m207.00--27.60--5.62-2.23-2.232.330.46640.74091.537.30290,048.30-70.74---86.14--86.46---95.47--3.37-11.270.7768--45.68---32.69------
enGene Holdings Inc0.00-123.44m339.13m33.00--1.47-----4.77-4.770.005.210.00----0.00-78.13---84.20-------------3.140.0906-------260.87------
Codexis Inc64.45m-62.09m352.37m174.00--4.80--5.47-0.878-0.8780.91490.9020.42597.033.62370,379.30-41.03-17.13-54.21-20.2375.9677.29-96.35-37.043.15--0.2806---49.392.97-126.96--9.80--
XOMA Royalty Corp21.61m-35.43m354.31m13.00--4.17--16.40-3.06-3.061.867.210.1244--39.721,662,000.00-17.25-4.55-18.97-4.94-----138.67-31.87----0.5817---21.06-2.13-105.10--23.16--
Prime Medicine Inc800.00k-219.25m356.49m234.00--2.06--445.61-2.05-2.050.00731.440.0028----3,418.80-76.67---88.64-------27,406.13------0.00-------39.52------
Silence Therapeutics plc22.53m-50.47m358.35m115.00--5.45--15.91-0.4057-0.40570.181.010.1273--2.56195,915.70-28.51-43.60-32.89-54.9156.40---224.01-287.30----0.0016--44.99---6.86--156.10--
Northwest Biotherapeutics Inc1.60m-75.96m367.18m25.00------230.06-0.0631-0.06310.0013-0.04990.0525----63,840.00-244.93-381.58---------4,666.29-6,479.25---27.91----14.8036.2138.71--77.88--
Alector Inc61.51m-158.41m368.23m241.00--3.10--5.99-1.71-1.710.66071.210.1035----252,082.00-26.66-20.00-35.58-23.81-----257.54-124.07----0.00---27.3628.522.19--4.79--
Contineum Therapeutics Inc0.00-35.46m369.65m31.00--1.76-----1.39-1.390.008.170.00----0.00-19.97---20.75--------------0.00------193.68------
Ginkgo Bioworks Holdings Inc217.95m-651.19m378.79m1.22k--0.4384--1.74-12.90-12.904.2915.030.1243--5.01178,941.70-37.13---40.39--80.94---298.78------0.00---47.36--57.58------
ProQR Therapeutics NV22.33m-25.07m382.31m157.00--11.62--17.12-0.3075-0.30750.27380.31060.1713----142,198.80-19.24-35.51-26.22-40.51-----112.31-926.31----0.4105--118.5110.5856.35--34.45--
Verve Therapeutics Inc24.40m-197.03m389.45m255.00--0.7656--15.96-2.46-2.460.30336.010.0382--8.4595,670.59-30.87---32.86-------807.62------0.00--505.77---27.12------
Data as of Nov 22 2024. Currency figures normalised to XOMA Royalty Corp's reporting currency: US Dollar USD

Institutional shareholders

56.59%Per cent of shares held by top holders
HolderShares% Held
BVF Partners LPas of 30 Sep 20243.63m31.05%
Fidelity Management & Research Co. LLCas of 30 Sep 20241.04m8.93%
BlackRock Fund Advisorsas of 30 Sep 2024492.23k4.21%
The Vanguard Group, Inc.as of 30 Sep 2024410.24k3.51%
Opaleye Management, Inc.as of 30 Sep 2024250.00k2.14%
Stonepine Capital Management LLCas of 30 Sep 2024195.10k1.67%
Geode Capital Management LLCas of 30 Sep 2024182.74k1.56%
Morgan Stanley Investment Management, Inc.as of 30 Sep 2024151.78k1.30%
SSgA Funds Management, Inc.as of 30 Sep 2024142.86k1.22%
TLS Advisors LLCas of 30 Sep 2024119.74k1.02%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.